Cargando…

Direct Photocoagulation Guided by Merged Retinal Images for the Treatment of Focal Diabetic Macular Edema

PURPOSE: To introduce a novel laser photocoagulation (PC) protocol named merged image-guided PC (MIG-PC), which included merging the images of the fundus, optical coherence tomography (OCT) map, and fluorescein angiography (FA). We compared the anatomical and functional results between MIG-PC and FA...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamura, Yoshihiro, Matsumura, Takehiro, Arimura, Shogo, Gozawa, Makoto, Morioka, Masakazu, YutakaYamada, Inatani, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867680/
https://www.ncbi.nlm.nih.gov/pubmed/29721014
http://dx.doi.org/10.1155/2018/2401094
Descripción
Sumario:PURPOSE: To introduce a novel laser photocoagulation (PC) protocol named merged image-guided PC (MIG-PC), which included merging the images of the fundus, optical coherence tomography (OCT) map, and fluorescein angiography (FA). We compared the anatomical and functional results between MIG-PC and FA-guided PC (FG-PC) for the treatment of focal diabetic macular edema (DME). METHOD: We examined the treatment outcomes in 27 consecutive eyes treated with MIG-PC compared with 28 matched eyes treated with FG-PC. We identified the microaneurysms (MAs) located in the focal edema areas and ablated them using focal PC. Best-corrected visual acuity (BCVA) and retinal thickness (RT) measured using OCT were compared between the groups at baseline and 2, 4, 8, 12, and 24 weeks after treatment. RESULTS: The foveal and perifoveal RT were reduced after treatment in both the groups, and the perifoveal RT in the MIG-PC group was significantly lower than that in the FG-PC group at 4 weeks and thereafter. BCVA in the MIG-PC group was significantly higher than that in the FG-PC group at 12 and 24 weeks. The numbers of laser spots (p = 0.0001), additional laser treatments (p = 0.0121), and intravitreal injection of ranibizumab (p = 0.0012) in the MIG-PC group were significantly lower than those in the FG-PC group (Mann–Whitney test). CONCLUSION: MIG-PC contributed to the improvement in BCVA and reduction in RT, number of laser shots required, and retreatment rates. Based on our data, MIG-PC can be recommended for the treatment of focal DME. This trial is registered with ID UMIN000030390.